Roivant Sciences Ltd. $ROIV Shares Sold by BlackBarn Capital Partners LP

BlackBarn Capital Partners LP lessened its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 2.6% during the second quarter, Holdings Channel reports. The firm owned 4,625,000 shares of the company’s stock after selling 125,000 shares during the period. Roivant Sciences makes up about 3.0% of BlackBarn Capital Partners LP’s holdings, making the stock its biggest holding. BlackBarn Capital Partners LP’s holdings in Roivant Sciences were worth $52,124,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in ROIV. State Street Corp increased its holdings in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after buying an additional 911,827 shares during the last quarter. Two Seas Capital LP grew its position in Roivant Sciences by 4.6% during the second quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock valued at $119,440,000 after acquiring an additional 461,733 shares during the period. Invesco Ltd. increased its stake in Roivant Sciences by 3.8% during the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock worth $99,695,000 after acquiring an additional 365,468 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Roivant Sciences by 12.7% during the second quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after acquiring an additional 506,219 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Roivant Sciences in the 1st quarter worth about $31,988,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Citigroup increased their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research report on Thursday, September 18th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. HC Wainwright upped their price target on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $23.31.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $22.10 on Friday. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $22.45. The company has a market capitalization of $15.37 billion, a PE ratio of -39.46 and a beta of 1.22. The business has a 50-day moving average of $19.38 and a 200-day moving average of $14.68.

Insider Buying and Selling at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 539,650 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $20.51, for a total transaction of $11,068,221.50. Following the completion of the sale, the insider owned 33,653,756 shares of the company’s stock, valued at approximately $690,238,535.56. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $20.85, for a total transaction of $4,170,000.00. Following the completion of the sale, the chief executive officer owned 1,497,908 shares of the company’s stock, valued at approximately $31,231,381.80. This trade represents a 11.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,907,812 shares of company stock worth $125,271,540 in the last 90 days. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.